Skip to contentC
Cryo Cell International Inc
C
CCELCryo Cell International Inc Q2 2024 · 10-Q
Revenue$8.04M$8.04M+3.5% vs Q2 2023 Net Income$655.79K$655.79K+196.8% vs Q2 2023 EPS Diluted$0.08$0.08+166.7% vs Q2 2023 Operating Income$1,391,518+35.4% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cryo Cell International Inc · CIK 862692 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$21,549−95.9% Margins · derivedOperating margin17.3%+4.1 pt vs Q2 2023
Net margin8.2%+5.3 pt vs Q2 2023
ended May 31, 2024 · filed Jul 15, 2024 · 45 d after period end